Patents
Sitemap › A61 - Medical or veterinary science; Hygiene › A61P - Specific therapeutic activity of chemical compounds or medicinal preparations › A61P 43 - Drugs for specific purposes, not provided for in groups
Patents for A61P 43 - Drugs for specific purposes, not provided for in groups (156,317)
03/2003
03/20/2003US20030055039 For prophylaxis and therapy of inflammatory disease
03/20/2003US20030055037 Benzimidazole and indole derivatives as CRF receptor modulators
03/20/2003US20030055032 For therapy or inhibiting the development of a pathology associated with peroxynitrite damage
03/20/2003US20030055029 Combbretastatin a-4 as an anti-angiogenic agent
03/20/2003US20030055027 For therapy of circulatory disorders, including cardiovascular disorders such as hypertension, congestive heart failure, cirrhosis and ascites
03/20/2003US20030055026 Formoterol/steroid bronchodilating compositions and methods of use thereof
03/20/2003US20030055021 Compounds for the treatment of ischemia
03/20/2003US20030055019 Genes and proteins predictive and therapeutic for stroke, hypertension, diabetes and obesity
03/20/2003US20030055012 Prodrugs of COX-2 inhibitors
03/20/2003US20030055006 Combinations and compositions which interfere with VEGF/VEGF and angiopoietin/tie receptor function and their use
03/20/2003US20030055005 Gamma-secretase inhibitors
03/20/2003US20030055003 Administering copper chelator and activated protein C (APC) or protein C or agent that increases the synthesis of protein C in the animal, or both, an activator of protein C for therapy
03/20/2003US20030054996 Contacting complex comprising a GRP94 protein with a binding agent that is immobilized to a solid phase support, to immobilize the complex to solid phase support; collecting the remaining sample; eluting the complex from solid phase support
03/20/2003US20030054990 Methods of using neural thread proteins to treat tumors and other conditions requiring the removal or destruction of cells
03/20/2003US20030054974 Non-oxidatively metabolized compounds and compositions, synthetic pathways therefor, and uses thereof
03/20/2003US20030054549 Cell propagation mixture for use in the activation of stem cells
03/20/2003US20030054525 UDP-N-acetylglucosamine: galactose-beta1,3-N-acetylgalactosamine-alpha-R / (GlcNAc to GalNAc) beta1,6-N-acetylglucosaminyltransferase, C2GnT3
03/20/2003US20030054498 Recombinant vector for use in gene therapy for insulin-dependent diabetes mellitus and therapeutic composition thereof
03/20/2003US20030054491 Peptide for use in the treatment of immunological, infectious and cancer disorders
03/20/2003US20030054490 Isolated human phosphatase proteins, nucleic acid molecules encoding phosphatase proteins and uses thereof
03/20/2003US20030054452 Lysolipid for use in controlling apoptosis and treating inflammatory and innumological disorders
03/20/2003US20030054409 Novel complex-forming proteins
03/20/2003US20030054398 Isolated human aminotransferase proteins, nucleic acid molecules encoding aminotransferase proteins and uses thereof
03/20/2003US20030054052 Triterpene compositions and methods for use thereof
03/20/2003US20030054046 Hydrated dressing containing metal microbiocide
03/20/2003US20030054038 Mixture of drug and enteric acid polymer; neutralization
03/20/2003US20030054037 Pharmaceutical compositions of adsorbates of amorphous drug
03/20/2003US20030054014 Administering fungi spores; aging resistance
03/20/2003US20030053986 Method of treating hepatitis C infection
03/20/2003US20030053984 Bimer or an oligomer of a dimer, trimer, quadromer or pentamer of recombinant fusion proteins
03/20/2003US20030053981 Combinations of bile acid sequestrant(s) and sterol absorption inhibitor(s) and treatments for vascular indications
03/20/2003US20030053973 Topical composition for follicular delivery of an ornithine decarboxylase inhibitor
03/20/2003CA2460348A1 Methods of preparing and using 2-hydroxy derivatives of sibutramine and its metabolites
03/20/2003CA2460330A1 Method for the preparation of crystalline tetrahydrobenzothiepines
03/20/2003CA2460190A1 Transdermal administration of an enalapril ester
03/20/2003CA2460023A1 Method for treating coumarin-induced hemorrhage
03/20/2003CA2460022A1 Aryloxypropylamines as chemosensitizing agent in the treatment of cancer
03/20/2003CA2459973A1 Carbazole derivatives and their use as npy5 receptor antagonists
03/20/2003CA2459882A1 Thiophenylthiopyrane dioxides as mmp or tnf-alpha inhibitors
03/20/2003CA2459879A1 3-(4,5,6,7-tetrahydroindol-2-ylmethylidiene)-2-indolinone derivatives as kinase inhibitors
03/20/2003CA2459769A1 Igf-1 as feline vaccine adjuvant, in particular against feline retroviruses
03/20/2003CA2459766A1 Oxazolidinone and/or isoxazoline as antibacterial agents
03/20/2003CA2459760A1 Method for preparing unsaturated fatty hydroxy-acids and esters thereof, their use in pharmaceutical and/or cosmetic compositions
03/20/2003CA2459531A1 Heterocyclic substituted 2- (4-phenoxy) pyridine derivatives and related compounds as sodium channel blockers for the treatment of neuronal damage and neurodegenerative conditions
03/20/2003CA2459527A1 Aryl substituted pyridinecarboxamides and their use as sodium channel blockers
03/20/2003CA2459515A1 Indole derivatives
03/20/2003CA2459464A1 Tetrahydropyran derivatives and their use as therapeutic agents
03/20/2003CA2459364A1 Ccr-3 receptor antagonists v
03/20/2003CA2459318A1 Nucleic acid and corresponding protein entitled steap-1 useful in treatment and detection of cancer
03/20/2003CA2459168A1 Method for the preparation of hexahydro-furo[2,3-b]furan-3-ol
03/20/2003CA2458302A1 New assay for inhibitors of translocases
03/20/2003CA2457895A1 Prostaglandin compositions and methods of treatment for male erectile dysfunction
03/20/2003CA2457849A1 Use of hcg in controlled ovarian hyperstimulation
03/20/2003CA2457835A1 Crystalline forms of valacyclovir hydrochloride
03/20/2003CA2457717A1 Use of compounds in a dry powder inhaler
03/19/2003EP1293563A1 Inhibition of apoptosis by the expression of antisense rna of caspase-3
03/19/2003EP1293512A2 DNA encoding the baboon and cynomolgus macaque prostaglandin E2 receptor EP4 subtype
03/19/2003EP1293506A1 New 1-(1-(Hetero)aryl-1-perhydroxyalkylmethyl)-Piperazine derivatives, process for their preparation and pharmaceutical compositions containing the same
03/19/2003EP1293503A1 Triazole derivatives
03/19/2003EP1293205A1 Valproic acid and derivatives thereof for the combination therapy of human cancers, for the treatment of tumour metastasis and minimal residual disease
03/19/2003EP1292697A2 Method for preparing a physiologically active il-18 polypeptide
03/19/2003EP1292695A2 Gene-regulating conjugates
03/19/2003EP1292694A2 A recombinant non-replicating virus expressing gm-csf and uses thereof to enhance immune responses
03/19/2003EP1292685A2 Human lyases
03/19/2003EP1292683A2 Secreted redox proteins
03/19/2003EP1292676A1 Mutation associated with epilepsy
03/19/2003EP1292619A2 B7-related nucleic acids and polypeptides and their uses for immunomodulation
03/19/2003EP1292608A2 Novel compounds of the n-acylamino-amide family, compositions comprising same, and uses
03/19/2003EP1292605A2 Antisense modulation of inhibitor of dna binding-1 expression
03/19/2003EP1292604A1 2-aminocarbonyl-9h-purine derivatives
03/19/2003EP1292601A2 Naaladase inhibitors for treating retinal disorders and glaucoma
03/19/2003EP1292596A1 1,3,8-triaza-spiro[4,5]decan-4-one derivatives as neurokinin receptor antagonists
03/19/2003EP1292592A1 Heterocyclic aminoalkyl pyridine derivatives as psychopharmaceuticals
03/19/2003EP1292591A2 Substituted bicyclic derivatives for the treatment of abnormal cell growth
03/19/2003EP1292581A1 Bicyclic cyclohexylamines and their use as nmda receptor antagonists
03/19/2003EP1292579A1 Substituted polycyclic aryl and heteroaryl pyrazinones useful for selective inhibition of the coagulation cascade
03/19/2003EP1292576A1 Hydroxamic and carboxylic acid derivatives having mmp and tnf inhibitory activity
03/19/2003EP1292573A2 Substituted thioacetamides
03/19/2003EP1292572A1 Propanolaminotetralines, preparation thereof and compositions containing same
03/19/2003EP1292564A2 Aminoalcohol derivatives
03/19/2003EP1292563A2 Compounds useful for the preparation of medicaments with phosphodiesterase iv inhibitory activity
03/19/2003EP1292363A2 Carboxyalkylether-acat inhibitor combinations
03/19/2003EP1292340A1 Transfection system
03/19/2003EP1292338A2 Stabiliser for radiopharmaceuticals
03/19/2003EP1292336A2 Conjugates of aminodrugs comprising an oxime bond
03/19/2003EP1292324A2 Critical illness neuropathy
03/19/2003EP1292314A2 Method for treating respiratory disorders associated with pulmonary elastic fiber injury comprising the use of glycosaminoglycans
03/19/2003EP1292311A2 Combination therapy for the treatment of depression comprising an antidepressant and an ampa receptor potentiator
03/19/2003EP1292304A1 Zolpidem hemitartrate
03/19/2003EP1292301A1 Treatment and prevention of cardiac insulin resistance associated conditions
03/19/2003EP1292298A1 Intracorporeal medicaments for high energy phototherapeutic treatment of disease
03/19/2003EP1292297A1 Pharmaceutical combination of bicalutamide and anastrozole for providing an anti-androgenic effect and aromatase inhibition
03/19/2003EP1292296A1 Pharmaceutical combination of bicalutamide and tamoxifen for providing an anti-androgenic effect and an anti-oestrogenic effect
03/19/2003EP1292294A1 Use of medium chain triglycerides for the treatment and prevention of alzheimer's disease and other diseases resulting from reduced neuronal metabolism
03/19/2003EP1292293A1 Stabilized pharmaceutically effective composition and pharmaceutical formulation comprising the same
03/19/2003EP1292290A2 Pharmaceutical compositions comprising acryloyl distamycin derivatives and topoisomerase i and ii inhibitors
03/19/2003EP1292289A2 Compositions and methods for treating neoplastic disease using chemotherapy and radiation sensitizers
03/19/2003EP1292288A2 2-arachidonylglycerol (2-ag) - an inhibitor of tumor necrosis factor -alfa and neuroprotector of brain in closed head injury
03/19/2003EP1292281A1 Novel tiotropium-containing inhalation powder
03/19/2003EP1292279A1 The use of glatiramer acetate (copolymer 1) in the treatment of central nervous system disorders
1 ... 807 808 809 810 811 812 813 814 815 816 817 818 819 820 821 822 823 824 825 826 827 ... 1564